These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16083342)

  • 1. The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.
    Rogers SJ; Box C; Harrington KJ; Nutting C; Rhys-Evans P; Eccles SA
    Expert Opin Ther Targets; 2005 Aug; 9(4):769-90. PubMed ID: 16083342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck.
    Simpson DR; Mell LK; Cohen EE
    Oral Oncol; 2015 Apr; 51(4):291-8. PubMed ID: 25532816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
    Cai Y; Dodhia S; Su GH
    Oncotarget; 2017 Mar; 8(13):22203-22217. PubMed ID: 28108737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer.
    Cruz JJ; Ocaña A; Del Barco E; Pandiella A
    Ann Oncol; 2007 Mar; 18(3):421-30. PubMed ID: 16873430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer.
    Bussink J; van der Kogel AJ; Kaanders JH
    Lancet Oncol; 2008 Mar; 9(3):288-96. PubMed ID: 18308254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
    Isaacsson Velho PH; Castro G; Chung CH
    Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological significance of c-erbB family oncogenes in head and neck cancer.
    Rogers SJ; Harrington KJ; Rhys-Evans P; O-Charoenrat P; Eccles SA
    Cancer Metastasis Rev; 2005 Jan; 24(1):47-69. PubMed ID: 15785872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy for squamous cell carcinoma of the head and neck.
    Aldoss IT; Ganti AK
    J Egypt Natl Canc Inst; 2009 Jun; 21(2):157-66. PubMed ID: 21057567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor directed therapy in head and neck cancer.
    Choong NW; Cohen EE
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
    Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
    Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
    J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.
    Masuda M; Suzui M; Lim JT; Deguchi A; Soh JW; Weinstein IB
    J Exp Ther Oncol; 2002; 2(6):350-9. PubMed ID: 12440226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
    Machiels JP; Schmitz S
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-κB participates in chemokine receptor 7-mediated cell survival in metastatic squamous cell carcinoma of the head and neck.
    Liu FY; Zhao ZJ; Li P; Ding X; Guo N; Yang LL; Zong ZH; Sun CF
    Oncol Rep; 2011 Feb; 25(2):383-91. PubMed ID: 21165563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
    Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.